Study explores toxicity reduction in combination of trastuzumab deruxtecan and olaparib in HER2-expressing malignancies
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
12 hours ago
0
3









